TalkMed Group Limited Overview
TalkMed is a doctor-founded, asset-light specialist oncology services platform. Its core business is supplying medical oncologists, haematologists and clinical staff to Parkway Cancer Centre. Parkway Cancer Centre is a division of Parkway Hospitals Singapore that operates across Gleneagles, Mount Elizabeth, Mount Elizabeth Medical Centre and Mount Elizabeth Novena.
The model is unusual among listed healthcare companies:
-
It earns consultancy and management fees under a long-standing agreement with Parkway rather than owning hospitals.
-
This produced operating margins near 45–50% and a debt-free balance sheet holding S$80–90M of cash.
The franchise rests on the clinical reputation of four founder doctors led by Dr Ang Peng Tiam. This is both its key differentiator and its principal concentration risk.
Around the core, TalkMed built small regional oncology outposts in Vietnam and China and a cell and gene therapy contract manufacturing unit (CellVec). In September 2025 it became the Singapore anchor of Tamarind Health, a Templewater- and Temasek-backed pan-Asian oncology platform.
Company's own description (FY2024 Annual Report, paraphrased)
The company described itself as a premier provider of three services, serving patients in Singapore and the region:
-
medical oncology
-
stem cell transplants
-
palliative care
Outside Singapore it operated in Vietnam, Hong Kong (until the 2024 divestment by its associate) and the People's Republic of China. The FY2024 Annual Report also states:
-
SCC is among the market leaders in Singapore medical tourism.
-
Foreign patients accounted for more than half of its patient load in recent years.
-
Many of those patients came from Indonesia, Malaysia and Vietnam.
How the business makes money
The FY2024 results announcement (Note 4) describes two reportable segments. A third segment existed until FY2021.
1. Oncology services (94.1% of FY2024 revenue), earned in two ways:
Consultancy services: - SCC supplies specialist doctors and clinical staff to Parkway Cancer Centre (PCC). Revenue is computed under the Consultancy Restatement Agreement with Parkway Hospitals Singapore Pte. Ltd.
-
The Group supplies consultancy to Thu Cuc International General Hospital in Hanoi under a profit-sharing agreement.
-
It provides consultancy to patients directly in Beijing (TalkMed Shanshui Medical Centre) and Chongqing (Sino-Singapore Cancer Centre).
Management fees: SCC bills PCC for the salaries, wages, benefits and premises rental incurred in delivering oncology services. It also recovers expenses of SCC doctors serving Thu Cuc. This is largely a cost pass-through.
2. Cellular and gene therapy (CGT) products and services (5.9% of FY2024 revenue):
-
CellVec Pte. Ltd. (60%) manufactures GMP-grade lentiviral vectors for CAR-T and other cell therapies used in clinical trials.
-
BioCell Innovations Pte. Ltd. (60%) began operations in 2024 but booked no revenue that year.
3. Stem cell related products and services (discontinued):
- Stem Med Pte. Ltd. (55.2%) provided stem cell processing and storage until it was divested in October 2021.
Revenue model mix
| Revenue type | FY2024 | Share of total |
|---|---|---|
| Oncology consultancy services (service fees) | 44.70 | 57.2% |
| Oncology management fees (cost-recovery service) | 28.86 | 36.9% |
| CGT products and services (product/contract manufacturing) | 4.61 | 5.9% |
| Total | 78.18 | 100.0% |
There is no subscription or licensing revenue. Almost all revenue (S$77.76M in FY2024) is recognised over time as services are rendered.
Value-chain position, customers and end-markets
| Aspect | Detail |
|---|---|
| Direct contractual customer for most revenue | Parkway Hospitals Singapore, part of IHH Healthcare |
| Economic end-customers | Self-paying and insured cancer patients from Singapore and the region |
| CGT customers | Biotech companies, research institutes and large pharmaceutical companies in Australia, the US, New Zealand and elsewhere (FY2024 Annual Report) |
| End-markets | Private oncology and haematology in Singapore; regional medical tourism (Indonesia, Malaysia, Vietnam); private oncology in Beijing and Chongqing; cell and gene therapy contract manufacturing |
TalkMed sits at the physician-services layer of the private oncology value chain:
-
It controls the clinical relationship with the patient and the doctor talent.
-
It does not own the hospital infrastructure, pharmacy or wards, which belong to Parkway.
Independent characterisation
Analytically, TalkMed functioned as a capital-light, talent-centric professional partnership wrapped in a listed company:
Assets: its assets were its doctors' reputations and the Parkway contract. Fixed assets were minimal: PPE S$4.36M and right-of-use assets S$4.36M at end-FY2024.
Margins and capital intensity: EBITDA margins of 47–54% (derived, FY2020–FY2024) and capex below 1% of revenue in most years.
Payouts: the model supported dividend payouts of 70–130% of attributable profit.
The weaknesses are equally structural:
Founder dependence: revenue tracks the founder doctors (51.7% of FY2024 revenue, down from 68.2% in FY2020).
Single-doctor dependence: Dr Ang alone generated 31.8% of FY2024 revenue.
Policy exposure: the business is sensitive to Singapore health-financing policy, notably the Cancer Drug List introduced September 2022.
Weak diversification: every diversification attempt to date — China, Hong Kong, stem cells, CGT — consumed capital and produced losses or, at best, a one-off gain on exit.
Strategy
Stated strategy before privatisation (FY2024 Annual Report, results commentary and AGM, paraphrased)
Vision and mission: to be a premier private-sector provider of medical oncology and palliative care in Singapore and the region, eventually expanding into primary and secondary care.
Singapore:
-
Expand the foreign-patient base as regional air connectivity improves.
-
Optimise processes to absorb higher volumes.
-
Manage the impact of the Cancer Drug List; management expected local demand to stabilise and grow steadily in 2025.
China:
-
Grow patient numbers through operational improvement.
-
Collaborate with established hospitals and insurers.
-
Recruit experienced doctors and introduce differentiated services.
-
Increase visits to the China centres by Singapore experts.
Cell and gene therapy:
-
CellVec to broaden its client base (biotech, research institutes, pharma) and services, targeting stronger 2025 growth.
-
BioCell to start compassionate-use and safety CAR-T programmes in India.
ESG targets for FY2025:
-
Maintain carbon-emissions intensity.
-
At least 40 training hours per employee.
-
Zero fatalities, reportable injuries, corruption cases and data breaches.
-
Run a gap analysis against the ISSB S2 climate-disclosure standard.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Date | Initiative | Detail |
|---|---|---|
| Aug 2024 | Portfolio rationalisation | Exit from Hong Kong via HKH's sale of HKIOC; investment de-recognised at 31 Dec 2024 |
| 23 Dec 2024 | Strategic combination | Agreement for Tamarind Health to acquire TalkMed |
| 2,025 | China premises relocation | A China subsidiary was due to move to new premises in 2025 |
| Sep 2025 | Integration into Tamarind Health | Tamarind's stated rationale: sub-specialisation, shared infrastructure, research collaboration and clinical trials, streamlined billing, and a Singapore medical-tourism hub. TalkMed was to continue operating under its current brand. |
| Oct 2025 | Platform positioning | Tamarind describes itself as a doctor-led integrated oncology platform: more than 180,000 patient visits a year, more than 500 doctors and staff, 36 centres |
| Sep 2026 | Rare Cancer Centre | Tamarind launches a single access point for rare and complex cancers (haematologic malignancies and lymphoma, sarcoma, neuroendocrine tumours, brain and uncommon skin cancers), drawing on network oncologists |
| Long term | Potential relisting | The joint announcement stated the combined entity may consider a future SGX listing |
Medium-term financial targets / guidance
-
TalkMed never published quantitative medium-term targets. Guidance was qualitative ("cautiously optimistic"; "steady growth anticipated").
-
Tamarind Health does not publish financial guidance.
-
Not publicly disclosed.
Products & Services
Oncology services segment
| Offering | Description | Target customer | Since | Pricing model |
|---|---|---|---|---|
| Parkway Cancer Centre — medical oncology (brand owned by Parkway Hospitals Singapore; staffed by SCC doctors) | Multidisciplinary medical oncology. Covers consultation, examination, chemotherapy and systemic therapy administration, minor outpatient procedures, prescribing, laboratory and diagnostic orders, and follow-up. Delivered from 9 clinics at Gleneagles Hospital, Mount Elizabeth Hospital, Mount Elizabeth Medical Centre and Mount Elizabeth Novena Specialist Centre. | Private-pay and insured adult cancer patients from Singapore and the region | SCC from Nov 2006 | Consultancy fees under the Consultancy Restatement Agreement with Parkway, plus cost-recovery management fees. Detailed fee formula not publicly disclosed. |
| Haematology and stem cell transplantation | Treatment of adult and paediatric blood disorders and haematologic malignancies, including stem cell transplants. Nurse competency checklists include apheresis (handling blood products). | Patients with leukaemia, lymphoma, myeloma and benign blood disorders | Not separately dated | As above |
| Palliative care | Palliative healthcare services | Advanced-cancer patients and families | Not separately dated | As above |
| Singapore Cancer Centre Thu Cuc (Hanoi, Vietnam) | Oncology centre operated by Thu Cuc International General Hospital, with consultancy from SCC doctors | Vietnamese patients | Set up 2014 | Profit-sharing agreement. Revenue S$0.03M in FY2024. |
| TalkMed Shanshui Medical Centre (Beijing, PRC) | Private medical centre providing oncology and ancillary support services | PRC oncology patients | Aug 2021 | Direct patient billing. Consolidated in "China and Hong Kong" revenue (S$2.87M in FY2024). |
| Sino-Singapore Cancer Centre (Yongchuan, Chongqing, PRC) | Category 2A oncology hospital run through the 60:40 JV with Yongchuan District People's Hospital. Implemented a Diagnosis Related Group (DRG) charging system in Dec 2024. | Western Chongqing oncology patients | Jun 2021 | Equity-accounted, so revenue is not consolidated. The Group stopped recognising share of losses in 2H 2024 after cumulative losses equalled its investment. |
| Hong Kong Integrated Oncology Centre (30% associate, divested) | Oncology diagnostics and treatment with three clinics. Run with Hong Kong Adventist Hospital Oncology Centre since 2016. | Hong Kong and mainland patients | 2015–Aug 2024 | Equity-accounted, plus a fixed annual consultancy fee from TalkMed (S$0.275M in FY2022) |
| Chongqing Medtech Health Management (30% JV) | Helps partner hospitals establish internet hospitals and run internet pharmacies | PRC hospitals | Formed Aug 2021 | Not operational in 2024 |
Cellular and gene therapy segment
| Offering | Description | Customers | Since | Notes |
|---|---|---|---|---|
| CellVec — cGMP lentiviral vectors | Manufactures lentiviral vector batches compliant with current Good Manufacturing Practice. Delivered vectors for more than 8 CAR-T products. Its process, quality systems and proprietary plasmids have met Investigational New Drug application requirements internationally, and its products are used in clinical trials. | Small biotech companies, research institutes, large pharma. FY2024 revenue by geography: Australia S$1.66M, US S$2.12M, Singapore S$0.84M. | Incorporated Aug 2018 | Contract manufacturing. Revenue is recognised at a point in time or over time depending on contract terms. Facility: freehold GMP unit at 100 Pasir Panjang Road (256 sqm). |
| CellVec — novel platform viral vector technologies | Development of platform technologies to advance genetic modification of cellular therapies; research into genetic modification of immune cells | Internal / partners | 2018 onward | Received SGInnovate funding (FY2024 other income disclosure). Amount not separately disclosed. |
| BioCell Innovations — humanised CD19-CAR | Aims to widen access to affordable CAR-T products with international collaborators. First product is a humanised CD19-CAR. Initial focus on India, where it is preparing compassionate-use and safety treatment programmes. | Patients with B-cell malignancies in the region, India first | Incorporated Jul 2023; operational 2024 | No revenue in FY2024 |
Discontinued / divested offerings
| Offering | Description | Period | Exit |
|---|---|---|---|
| Stem Med (including Stem Med Indonesia and DrSG Cellular Wellness) | Stem cell processing, culturing and storage; cellular laboratories and therapeutics clinics | Jan 2015 – Oct 2021 | Sold for fund units (US$811,000). Contingent consideration of up to 7,305 further Class C shares was subject to KPIs by 31 Mar 2023. The fund units were later fully impaired (FY2022–FY2023). |
Financial Narrative
All figures are in S$M unless stated. Sources:
-
FY2021, FY2022 and FY2024 full-year results announcements, which supply the comparative years (FY2020 from the FY2021 announcement; FY2023 from the FY2024 announcement)
-
FY2024 Annual Report and FY2024 AGM presentation
Results announcements are unaudited at release; prior-year comparatives within them are audited. TalkMed reports expenses by nature, so it does not report gross profit or cost of sales. Gross profit is therefore not reported and is omitted from the tables rather than estimated.
Income statement
Notes:
- FY2020 revenue growth uses FY2019 revenue of S$75.92M from the FY2024 Annual Report highlights.
EBIT (derived): PBT − share of associate − share of JVs − interest income + finance costs. It includes other income and impairments. FY2024 EBIT includes the S$2.77M gain on de-recognition of the associate; FY2021 includes the S$1.00M Stem Med disposal gain.
EBITDA (derived): EBIT + depreciation of right-of-use assets and PPE. It is on an SFRS(I) 16 basis, so lease costs sit below EBITDA.
Dividends per share by year: - FY2020: interim 0.60 + final 0.75
-
FY2021: 0.70 + 0.90
-
FY2022: 1.50 + 1.50
-
FY2023: 0.90 + 1.30
-
FY2024: 0.90 interim + 1.40 special; no final
Margins and growth (derived)
Further derived figures:
Revenue CAGR FY2020–FY2024: 5.9%. Measured from the pre-COVID FY2019 base of S$75.92M, the five-year CAGR is only 0.6%.
Company-defined "PAT before extraordinary items": S$27.48M in FY2024 versus S$31.32M in FY2023, down 12.3% (FY2024 AGM presentation).
Attributable profit excluding FY2024 one-offs: (associate gain share S$12.16M and de-recognition gain S$2.77M): about S$28.86M. This is a 10.3% decline versus FY2023 and a 36.9% adjusted net margin.
Balance sheet (31 December)
Notes:
-
TalkMed had no bank borrowings in any year.
-
"Debt" here is lease liabilities plus interest-free or discounted loans from CellVec's non-controlling shareholder to that subsidiary.
-
No goodwill or intangibles were recognised.
-
Non-controlling interests are negative because CellVec, a 60% subsidiary, has a deficit.
Cash flow
Notes:
-
FY2021 operating cash flow and lease principal are the restated comparatives in the FY2022 announcement (S$23.16M and S$2.11M). The FY2021 announcement originally reported S$23.45M and S$2.40M. The difference is a reclassification between operating and financing; the totals are unchanged.
-
FY2022 capex includes the S$4.01M purchase of the Pasir Panjang property.
-
FY2024 investing inflow includes S$14.35M of proceeds from de-recognition of the HKH associate.
Ratios (derived unless noted)
Notes:
- ROE uses the company's own definition and matches its AGM presentations. The payout ratio is company-reported.
ROIC: is not meaningful. Invested capital (equity + debt − cash) was close to zero or single-digit S$M every year, for example S$2.4M at end-FY2024, so ROIC computes to several hundred percent. ROCE is shown as the closest usable proxy.
Cash conversion cycle: cannot be calculated because the company does not report cost of sales or trade payables separately. Days sales outstanding is shown as the only computable component.
Commentary
Revenue trajectory.
FY2020–FY2021: revenue fell from the FY2019 peak of S$75.9M to S$62.1M in FY2020 and S$60.7M in FY2021. COVID-19 border measures choked off the foreign-patient flows on which SCC depends.
FY2022: the inflection came with Singapore's easing of community and border measures at end-March 2022. Revenue rose 26.1% to S$76.6M, with 2H 2022 alone up 38.4%.
FY2023: revenue reached a record S$83.8M.
FY2024: revenue declined 6.7%. Management attributed this to the Cancer Drug List introduced in September 2022, which tightened what MediShield Life, MediSave and Integrated Shield Plans reimburse and pushed some local patients toward public institutions. Foreign-patient revenue held steady and 2H 2024 recovered to S$45.1M.
Seasonality: the pronounced Q4 seasonality (Q4 FY2023 S$26.5M; Q4 FY2024 S$26.6M) suggests year-end treatment-cycle and billing effects. Management stated that the business is not significantly seasonal, so this pattern deserves diligence attention.
Cost structure.
-
Employee benefits run at 38–43% of revenue. They include doctor remuneration under revenue-sharing schemes, so the cost base is partly variable.
-
Other operating expenses rose from S$4.9M in FY2021 to S$8.9M in FY2024. Drivers were laboratory consumables for CellVec, professional and legal fees (including privatisation-related costs in FY2024), and drug consumables.
Below the operating line.
-
PRC joint-venture losses of S$1.0–1.9M a year and CGT segment losses of S$3.4–9.2M a year were a persistent drag throughout the period.
-
FY2024 PAT rose 44.4% to S$42.4M only because of one-offs: the S$12.16M share of HKH's gain on selling HKIOC and a S$2.77M de-recognition gain. On the company's own adjusted basis, PAT fell 12.3%.
Balance sheet and cash.
-
The group ended each year with S$79–90M in cash and no bank debt.
-
Operating cash flow conversion was strong, at roughly 100–140% of PAT excluding non-cash items.
-
Almost all free cash flow was distributed; FY2022 paid 130% of attributable profit.
-
In FY2024 dividends paid (S$47.8M) exceeded free cash flow (S$28.4M). The gap was funded by the HKH proceeds and a S$7.1M drawdown of cash.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Interest | Role |
|---|---|---|
Singapore Cancer Centre Pte. Ltd. | 100% | Core operating company; supplies doctors and staff to Parkway Cancer Centre |
TalkMed Vietnam Pte. Ltd. | 100% | Consultancy to Thu Cuc International General Hospital, Hanoi |
TalkMed Greater China Pte. Ltd. (TMGC) | 100% | PRC holding vehicle |
↳ TalkMed China Pte. Ltd. | 100% | Holds Beijing interests |
↳↳ Beijing Yachuang Siwei Investment Management Co., Ltd. | 90% equity plus 10% via contractual arrangements (100% deemed) | Investment and healthcare management |
↳↳↳ Beijing Deyi Shanshui Clinic Co., Ltd. | 100% | Operates TalkMed Shanshui Medical Centre, Beijing |
↳↳ TalkMed Hospital Management (Beijing) Co., Ltd. | 100% | Hospital management and advisory |
↳ TalkMed Chongqing Pte. Ltd. | 100% | Chongqing holding vehicle |
↳↳ Sino-Singapore Hospital Management (Chongqing) Co., Ltd. | 60% (equity-accounted joint venture) | Operates Sino-Singapore Cancer Centre with Yongchuan District People's Hospital (40%) |
↳↳ Chongqing Medtech Health Management Co., Ltd. | 30% (joint venture) | Internet hospital and pharmacy services; not operational in 2024 |
CellVec Pte. Ltd. | 60% | Lentiviral vector and CGT manufacturing |
BioCell Innovations Pte. Ltd. | 60% (StemCord 40%) | CAR-T (humanised CD19-CAR) commercialisation |
Hong Kong Integrated Oncology Centre Holdings Ltd. | 30% associate; de-recognised 31 Dec 2024 | Sold its operating subsidiaries Aug 2024; members' voluntary liquidation commenced in 2025 |
Revenue by Segment
| Segment | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Oncology services revenue (SGD Mn) | 61.11 | 59.75 | 73.36 | 81.03 | 73.57 |
Cellular and gene therapy revenue (SGD Mn) | 0.12 | 0.20 | 3.24 | 2.76 | 4.61 |
Stem cell services revenue (SGD Mn) | 0.91 | 0.80 | 0 | 0 | 0 |
Total revenue (SGD Mn) | 62.14 | 60.75 | 76.60 | 83.79 | 78.18 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansOncology revenue type
| Oncology revenue type | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Consultancy services (SGD Mn) | 39.42 | 37.79 | 48.17 | 51.75 | 44.70 |
Management fees (SGD Mn) | 21.68 | 21.97 | 25.19 | 29.28 | 28.86 |
Results by Segment
| Segment | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Oncology services segment profit (SGD Mn) | 28.48 | 26.50 | 32.68 | 36.20 | 45.81 |
Cellular and gene therapy segment profit (SGD Mn) | -9.24 | -4.54 | -3.69 | -6.85 | -3.41 |
Stem cell services segment profit (SGD Mn) | -0.72 | -0.54 | 0 | 0 | 0 |
Group profit after tax (SGD Mn) | 18.52 | 21.43 | 28.99 | 29.35 | 42.40 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Oncology revenue YoY growth (%) | 0 | -2.2 | 22.8 | 10.5 | -9.2 |
CGT revenue YoY growth (%) | 0 | 61.8 | 1,526.6 | -14.7 | 67.1 |
Oncology share of revenue (%) | 98.3 | 98.4 | 95.8 | 96.7 | 94.1 |
CGT share of revenue (%) | 0.2 | 0.3 | 4.2 | 3.3 | 5.9 |
Oncology segment profit margin (%) | 46.6 | 44.4 | 44.5 | 44.7 | 62.3 |
CGT segment profit margin (%) | -7,512.2 | -2,280.9 | -113.9 | -248.1 | -73.9 |
Income Statement and Margin Analysis (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Revenue (SGD Mn) | 62.14 | 60.75 | 76.60 | 83.79 | 78.18 |
Revenue YoY growth (%) | -18.2 | -2.2 | 26.1 | 9.4 | -6.7 |
Employee benefits expense (SGD Mn) | 24.38 | 26.04 | 29.44 | 33.78 | 33.44 |
Other operating expenses (SGD Mn) | 5.16 | 4.86 | 5.16 | 7.79 | 8.89 |
Depreciation and amortisation (SGD Mn) | 3.51 | 2.49 | 2.54 | 2.79 | 3.17 |
Impairment losses (SGD Mn) | 3.41 | 0 | 0.64 | 1.97 | 0.02 |
Operating income / EBIT (SGD Mn, derived) | 25.71 | 28.42 | 38.57 | 37.06 | 35.47 |
EBITDA (SGD Mn, derived) | 29.22 | 30.91 | 41.11 | 39.85 | 38.64 |
Interest income (SGD Mn) | 0.71 | 0.33 | 0.88 | 2.61 | 2.55 |
Finance costs (SGD Mn) | 0.52 | 0.39 | 0.35 | 0.36 | 0.28 |
Share of associate results (SGD Mn) | -1.04 | -0.06 | -0.33 | 0.07 | 12.38 |
Share of joint venture results (SGD Mn) | -0.04 | -1.02 | -1.92 | -1.57 | -0.69 |
Profit before tax (SGD Mn) | 24.81 | 27.29 | 36.85 | 37.82 | 49.44 |
Income tax expense (SGD Mn) | 6.29 | 5.86 | 7.86 | 8.46 | 7.04 |
Profit after tax (SGD Mn) | 18.52 | 21.43 | 28.99 | 29.35 | 42.40 |
Non-controlling interests share (SGD Mn) | -4.25 | -3.69 | -1.56 | -2.82 | -1.40 |
Net income attributable to owners (SGD Mn) | 22.77 | 25.12 | 30.55 | 32.18 | 43.79 |
Basic EPS (S$ cents) | 1.73 | 1.90 | 2.31 | 2.43 | 3.30 |
Diluted EPS (S$ cents) | 1.72 | 1.89 | 2.30 | 2.42 | 3.27 |
Dividend per share declared for year (S$ cents) | 1.35 | 1.60 | 3.00 | 2.20 | 2.30 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
EBIT margin (%) | 41.4 | 46.8 | 50.3 | 44.2 | 45.4 |
EBITDA margin (%) | 47.0 | 50.9 | 53.7 | 47.6 | 49.4 |
Pre-tax margin (%) | 39.9 | 44.9 | 48.1 | 45.1 | 63.2 |
PAT margin (%) | 29.8 | 35.3 | 37.8 | 35.0 | 54.2 |
Net margin, attributable (%) | 36.6 | 41.3 | 39.9 | 38.4 | 56.0 |
Effective tax rate (%) | 25.4 | 21.5 | 21.3 | 22.4 | 14.2 |
Employee benefits / revenue (%) | 39.2 | 42.9 | 38.4 | 40.3 | 42.8 |
Balance Sheet and Per-Share Data
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Total assets (SGD Mn) | 104.62 | 108.79 | 109.17 | 115.79 | 106.79 |
Cash and short-term deposits (SGD Mn) | 79.43 | 82.16 | 80.59 | 89.90 | 82.78 |
Trade and other receivables, current (SGD Mn) | 10.30 | 9.00 | 11.82 | 11.44 | 13.44 |
Property, plant and equipment (SGD Mn) | 2.02 | 2.35 | 6.00 | 4.99 | 4.36 |
Right-of-use assets (SGD Mn) | 4.16 | 6.17 | 4.08 | 4.67 | 4.36 |
Goodwill and intangibles (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Short-term debt incl. current leases and NCI loans (SGD Mn) | 1.79 | 1.98 | 1.85 | 4.73 | 4.99 |
Long-term debt incl. non-current leases and NCI loans (SGD Mn) | 8.35 | 7.04 | 5.23 | 4.45 | 3.73 |
Total debt (SGD Mn) | 10.13 | 9.02 | 7.09 | 9.18 | 8.71 |
Net debt (SGD Mn, negative = net cash) | -69.30 | -73.15 | -73.50 | -80.72 | -74.07 |
Total liabilities (SGD Mn) | 25.87 | 21.29 | 24.62 | 31.73 | 30.33 |
Equity attributable to owners (SGD Mn) | 83.43 | 90.18 | 88.71 | 90.12 | 83.96 |
Non-controlling interests (SGD Mn) | -4.68 | -2.68 | -4.17 | -6.06 | -7.51 |
Total equity (SGD Mn) | 78.76 | 87.50 | 84.55 | 84.06 | 76.46 |
Working capital / net current assets (SGD Mn) | 73.90 | 78.18 | 75.40 | 75.82 | 71.26 |
NAV per share (S$ cents) | 6.33 | 6.83 | 6.71 | 6.80 | 6.32 |
Shares outstanding at year-end (M) | 1,318.05 | 1,320.11 | 1,322.55 | 1,325.52 | 1,329.14 |
Cash Flow
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Operating cash flow (SGD Mn) | 31.27 | 23.16 | 37.18 | 41.73 | 28.80 |
Capex incl. property purchase (SGD Mn) | 1.95 | 0.77 | 4.33 | 0.70 | 0.39 |
Free cash flow (SGD Mn, OCF − capex) | 29.32 | 22.39 | 32.85 | 41.02 | 28.41 |
Lease principal repaid (SGD Mn) | 1.56 | 2.11 | 2.01 | 2.13 | 2.12 |
Free cash flow after leases (SGD Mn) | 27.76 | 20.28 | 30.84 | 38.90 | 26.29 |
Dividends paid (SGD Mn) | 25.04 | 19.14 | 31.73 | 31.79 | 47.76 |
Share buybacks (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Income tax paid (SGD Mn) | 5.71 | 9.10 | 5.89 | 7.86 | 8.38 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
ROE, attributable profit / year-end attributable equity (%) | 27.3 | 27.9 | 34.4 | 35.7 | 52.2 |
ROA, PAT / total assets (%) | 17.7 | 19.7 | 26.6 | 25.4 | 39.7 |
ROCE, EBIT / (total equity + total debt) (%) | 28.9 | 29.4 | 42.1 | 39.8 | 41.6 |
Current ratio (x) | 5.24 | 6.49 | 4.89 | 3.78 | 3.68 |
Debt / equity (x) | 0.13 | 0.10 | 0.08 | 0.11 | 0.11 |
Net debt / EBITDA (x) | -2.37 | -2.37 | -1.79 | -2.03 | -1.92 |
Interest coverage, EBIT / finance costs (x) | 49.2 | 72.7 | 111.5 | 104.1 | 129.0 |
Asset turnover, revenue / total assets (x) | 0.59 | 0.56 | 0.70 | 0.72 | 0.73 |
Days sales outstanding (days) | 60.5 | 54.1 | 56.3 | 49.8 | 62.7 |
Dividend payout, declared / attributable profit (%) | 78.2 | 84.2 | 130.0 | 90.6 | 69.7 |
FY2020 by Quarter
| Quarter | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Q1 revenue (SGD Mn) | 15.4 | 14.1 | 12.9 | 18.9 | 16.0 |
Q2 revenue (SGD Mn) | 15.3 | 14.8 | 19.5 | 18.9 | 17.1 |
Q3 revenue (SGD Mn) | 14.1 | 15.3 | 20.1 | 19.5 | 18.5 |
Q4 revenue (SGD Mn) | 17.3 | 16.5 | 24.1 | 26.5 | 26.6 |
Revenue source
| Revenue source | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Founder doctors share of revenue (%) | 68.2 | 64.3 | 61.4 | 55.5 | 51.7 |
Dr Ang Peng Tiam share of revenue (%) | 45.5 | 42.4 | 40.7 | 37.0 | 31.8 |
Number of doctors (Singapore) | 14 | 15 | 16 | 17 | 15 |
Number of clinics (Singapore) | 9 | 9 | 9 | 9 | 9 |
Revenue by Region
| Region | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Singapore (SGD Mn) | 61.26 | 59.58 | 72.50 | 78.80 | 71.51 |
China and Hong Kong (SGD Mn) | 0.40 | 0.89 | 0.79 | 2.16 | 2.87 |
Vietnam (SGD Mn) | 0.19 | 0.13 | 0.07 | 0.08 | 0.03 |
Australia (SGD Mn) | 0.12 | 0.09 | 2.56 | 1.20 | 1.66 |
United States (SGD Mn) | 0 | 0 | 0 | 0.55 | 2.12 |
New Zealand (SGD Mn) | 0 | 0 | 0 | 1.01 | 0 |
Other markets incl. Malaysia, Indonesia, Philippines, India (SGD Mn) | 0.17 | 0.07 | 0.67 | 0 | 0 |
Total (SGD Mn) | 62.14 | 60.75 | 76.60 | 83.79 | 78.18 |
Region Margins & Growth (%) and Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Singapore YoY growth (%) | -2.7 | 21.7 | 8.7 | -9.3 |
China and Hong Kong YoY growth (%) | 119.6 | -10.5 | 171.4 | 33.0 |
Vietnam YoY growth (%) | -31.9 | -43.7 | 15.5 | -63.4 |
Singapore share of total revenue (%) | 98.1 | 94.6 | 94.0 | 91.5 |
Geography Overview
| Geography | Oncology consultancy | Oncology management fees | Cellular and gene therapy | Total |
|---|---|---|---|---|
Singapore | 41.95 | 28.72 | 0.84 | 71.51 |
China and Hong Kong | 2.74 | 0.13 | 0 | 2.87 |
Vietnam | 0.01 | 0.02 | 0 | 0.03 |
Australia | 0 | 0 | 1.66 | 1.66 |
United States | 0 | 0 | 2.12 | 2.12 |
Total | 44.70 | 28.86 | 4.61 | 78.18 |
Share Price History
| Date | Price (SGD) | Source / note |
|---|---|---|
30 Jan 2014 | 0.10 | IPO placement price S$0.20, adjusted for the 1:1 bonus (derived) |
28 Jun 2017 | 0.74 | Intraday price on suspension news (The Edge) |
24 Apr 2018 | 0.70 | Close (The Edge) |
20 Feb 2024 | 0.365 | Close (The Edge) |
5 Apr 2024 | 0.380 | Last undisturbed price before the offer approach (joint announcement) |
3-year range to 5 Apr 2024 | 0.355–0.440 | Lowest and highest closing prices, derived from the scheme premia of 28.5% and 3.6% |
Dec 2024 (pre-announcement) | 0.44 | Last traded (The Edge) |
Scheme price | 0.456 | Cash, paid 11 Sep 2025 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
Equity value | S$606.1M | 1,329.14M shares × S$0.456 |
Enterprise value | about S$532.0M | Equity value − cash S$82.8M + leases S$4.4M + NCI loans S$4.3M (31 Dec 2024) |
P/E, FY2024 reported | 13.8x | Attributable profit S$43.8M |
P/E, FY2024 adjusted | 21.0x | Attributable profit excluding one-offs, about S$28.9M |
P/E, FY2023 | 18.8x | Attributable profit S$32.2M |
EV/EBITDA, FY2024 | 13.8x | EBITDA S$38.6M; 14.8x excluding the S$2.77M gain |
EV/EBITDA, FY2023 | 13.3x | EBITDA S$39.9M |
EV/Sales, FY2024 | 6.8x | Revenue S$78.2M |
P/B, 31 Dec 2024 | 7.2x | Attributable equity S$84.0M |
Dividend yield at scheme price | 5.0% | FY2024 DPS 2.30 cents (incl. 1.40 special); 2.0% on ordinary 0.90 cents |
Dividend
| Dividend | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Interim dividend (cents) | 0.60 | 0.70 | 1.50 | 0.90 | 0.90 |
Special dividend (cents) | 0 | 0 | 0 | 0 | 1.40 |
Final dividend (cents) | 0.75 | 0.90 | 1.50 | 1.30 | 0 |
Total dividend (cents) | 1.35 | 1.60 | 3.00 | 2.20 | 2.30 |
Total dividend declared (SGD Mn, AGM chart) | 17.8 | 21.1 | 39.7 | 29.2 | 30.5 |
Payout ratio (%) | 78.2 | 84.2 | 130.0 | 90.6 | 69.7 |
Analyst Conclusions
Guidance and expectations
Management's last guidance (February–April 2025): - Singapore oncology demand stabilising, with steady growth in patient volumes expected in 2025.
-
Foreign-patient demand expected to expand.
-
China growth through collaborations and recruitment.
-
CellVec expected to deliver higher demand and growth in 2025.
Consensus: no consensus forecasts exist; the company is delisted.
FY2025 onward: actual performance is not publicly disclosed.
Bull case (as a Tamarind Health asset or future IPO component)
-
Margin and cash quality is rare in healthcare services. Derived EBITDA margins of 47–54% and S$29–41M of annual free cash flow on under S$1M of capex make TalkMed a high-quality cash engine to fund Tamarind's regional build-out.
-
Founder dependence was falling before the deal. The founder share of revenue fell from 68.2% (FY2020) to 51.7% (FY2024), and Dr Ang's from 45.5% to 31.8%. Embedding the practice in a 500-plus-staff platform with sub-specialty groups and a Rare Cancer Centre should continue institutionalising the franchise.
-
The Cancer Drug List shock appears cyclical rather than structural for the foreign-patient book. Foreign-patient revenue held steady in FY2024. 2H 2024 revenue (S$45.1M) was within 2% of 2H 2023, and Q4 FY2024 (S$26.6M) was a record.
Bear case
-
Key-person risk was only priced, not removed. The scheme itself made Dr Ang's death or incapacity a termination event. Doctors fell from 17 to 15 in FY2024. Post-deal, founder incentives shift from dividend income to illiquid parent equity.
-
Organic growth is weak. FY2024 revenue was only 3% above FY2019. Excluding one-offs, FY2024 attributable profit fell about 10%. Every non-core venture since IPO (Hong Kong, China, stem cells, CGT) has generated impairments or losses, with the one exception of the HKIOC sale.
-
Structural policy and price headwinds: the Cancer Drug List and Integrated Shield Plan rider changes, a strong Singapore dollar, and lower-cost Thai and Malaysian alternatives cap Singapore pricing. Dependence on the Parkway contract leaves bargaining power with IHH.
Catalysts and monitorables (next 12 months)
-
Any Tamarind Health capital-markets activity, including the SGX relisting option flagged in December 2024.
-
Renewal or renegotiation of the Parkway Consultancy Restatement Agreement, and the founder doctors' new service agreements.
-
Doctor headcount and recruitment within the TalkMed practice.
-
Ministry of Health revisions to the Cancer Drug List and Integrated Shield Plan rules.
-
Progress of CellVec revenue and BioCell's India CAR-T programme.
-
Performance of the China centres after the 2025 premises relocation and DRG billing in Chongqing.
-
Tamarind disclosures on network patient volumes, and any further acquisitions or disposals of non-core TalkMed assets (CGT, China).
Concluding analyst verdict
TalkMed's eleven-and-a-half years as a listed company tell a consistent story. At its core was an outstanding professional-services franchise, wrapped in a corporate structure that never found a second engine.
The Parkway Cancer Centre practice was the economic substance. Built by Dr Ang Peng Tiam and three fellow founders, it generated derived EBITDA margins of roughly 50%, carried no bank debt, held S$80–90M of cash, and returned more than S$155M in dividends over FY2020–FY2024 alone.
Shareholders paid for that quality with three concentrations:
People: the founders still generated over half of revenue in FY2024.
Partner: effectively all Singapore oncology revenue ran through Parkway.
Policy: the Cancer Drug List visibly dented FY2024 revenue.
Diversification into Hong Kong, China, stem cells and cell and gene therapy consumed management attention and capital. It produced recurring losses; only the Hong Kong exit delivered a gain.
The S$0.456 scheme price valued the equity at about S$606M. That is roughly 14x trailing EBITDA and 21x one-off-adjusted earnings, a 20% premium to the undisturbed price. For minority holders confined by negligible liquidity, the deal was fair: it offered an exit near the top of the three-year trading range.
For Tamarind Health, TalkMed is the logical Singapore anchor. It combines Parkway Cancer Centre's referral franchise with OncoCare and sister practices to create the region's largest private, doctor-led oncology network. Strategically, the transaction converts key-person risk into a platform-retention problem. It is managed through founder reinvestment, board seats and renewed service agreements rather than eliminated.
The investment case now rests on four execution tests:
-
Can Tamarind institutionalise sub-specialty care and the Rare Cancer Centre fast enough?
-
Can it keep the founder doctors engaged?
-
Can it hold Parkway economics steady?
-
Can it lift growth above the near-flat FY2019–FY2024 trajectory?
Verdict: a high-quality, low-growth cash franchise whose value now depends on platform integration. Monitor any relisting of the combined entity closely; TalkMed alone was not a compelling growth story.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | Age (AR2024) |
|---|---|---|---|---|---|
Dr Ang Peng Tiam | Executive Director and Group CEO; Medical Director and Senior Consultant, Parkway Cancer Centre (Mount Elizabeth) | Director since 10 Sep 2013 | Founding Head of Medical Oncology at Singapore General Hospital (1991–1997); Clinical Associate Professor; fellowships at MD Anderson and Stanford | MBBS (Singapore); MMed Internal Medicine (NUS); FAMS, FACP, FRCP (Edin), FRCP (Lond) | 66 |
Dr Khoo Kei Siong | Group COO; Alternate Director to Dr Ang; Deputy Medical Director, Parkway Cancer Centre (Gleneagles) | Executive Director until 31 Dec 2023; alternate director thereafter | Senior Consultant at National Cancer Centre Singapore (1999–2004); Head of Medical Oncology there (2001–2004) | MBBS (Singapore); MMed Internal Medicine (NUS); FRCP (Edin); FAMS | 63 |
Lee Boon Yong | Group CFO; Company Secretary | Since 1 Sep 2014 | nTan Corporate Advisory; EY (audit, transaction advisory) | B.Acc (NTU, 2002); ISCA; CA ANZ | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | First appointed | Background | Age |
|---|---|---|---|---|
S. Chandra Das | Non-Independent Non-Executive Chairman; RC member | 23 Dec 2013 | Former MP (1980–1996); former chairman of the Trade Development Board and NTUC FairPrice; Non-Resident High Commissioner to Sri Lanka; NTU Pro-Chancellor | 84 |
Dr Ang Peng Tiam | Executive Director and CEO; NC member | 10 Sep 2013 | See above | 66 |
Sitoh Yih Pin | Non-Independent Non-Executive Director; ARC member | 23 Dec 2013 | Chartered Accountant; MP for Potong Pasir | 61 |
Prof Leong Ching Ching | Independent Director; RC Chairperson | 1 Oct 2021 | Vice Provost (Student Life), NUS; Lee Kuan Yew School of Public Policy | 55 |
Peter Sim Swee Yam | Independent Director; NC Chairman; ARC member | 1 Jan 2024 | Lawyer with more than 42 years of practice (Sim Law Practice); independent director of Singapore Land Group | 69 |
Lam Kok Shang | Independent Director; ARC Chairman; NC member | 1 Jan 2024 | Former KPMG Singapore partner (head of Indirect Tax); GST Board of Review member 2013–2018 | 61 |
Dr Tan Khai Tong | Independent Director; RC member | 1 Jan 2024 | Consultant endocrinologist; National Healthcare Group board member 2014–2023 | 66 |
Directors' Remuneration
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
Total key management compensation (SGD Mn) | 7.50 | 8.18 | 8.60 | 8.61 | 8.47 |
Paid to directors of the Company (SGD Mn) | 6.20 | 6.21 | 6.33 | 6.33 | 6.34 |
Paid to other key management (SGD Mn) | 1.29 | 1.96 | 2.27 | 2.28 | 2.13 |
Directors' fees, Company and subsidiaries (SGD Mn) | 0.38 | 0.39 | 0.50 | 0.50 | 0.51 |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
Ladyhill Holdings Pte. Ltd. (72% owned by Dr Ang; Dr Ang and spouse Mdm Chua Siok Lin deemed interested) | 858,912,000 | 64.62 |
Dr Khoo Kei Siong | 99,360,000 | 7.48 |
Dr Teo Cheng Peng | 98,256,000 | 7.39 |
Dr Lim Hong Liang | 47,472,000 | 3.57 |
Founder doctors and Ladyhill combined | 1,104,000,000 | 83.06 |
Other directors combined (Das via spouse, Prof Leong, Dr Tan) | 1,460,300 | 0.11 |
Free float (derived) | about 224M | about 16.8 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Positioning vs TalkMed |
|---|---|---|---|
Private oncology, Singapore | OncoCare Medical (now a sister company under Tamarind) | Private group practice | Formerly the closest rival; now consolidated with TalkMed under one parent |
Private oncology, Singapore | Icon Cancer Centre (Singapore) | Private oncology/radiotherapy chain | Integrated radiation and medical oncology. |
Private oncology, Singapore | Raffles Cancer Centre (Raffles Medical Group, SGX: BSL) | Hospital-based | Vertically integrated hospital competitor |
Private oncology, Singapore | Thomson Medical Group (SGX: A50) oncology services | Hospital and clinic group | Smaller oncology presence |
Private hospital platform | IHH Healthcare / Parkway Pantai (Bursa: IHH) | Hospital owner | Both landlord/partner and potential competitor if it employs oncologists directly |
Public oncology, Singapore | National Cancer Centre Singapore (SingHealth) | Public | Lower-cost alternative; benefits from Cancer Drug List and insurer shifts |
Public oncology, Singapore | National University Cancer Institute, Singapore (NUHS) | Public | As above |
Regional private oncology | TE Asia Healthcare Partners (TPG-backed) | Specialty platform | Oncology, cardiology and orthopaedics across SE Asia and Hong Kong |
Regional medical tourism, Thailand | Bumrungrad International; Bangkok Dusit Medical Services | Hospital groups | Lower-cost destinations; the FY2024 Annual Report notes Thailand and Malaysia as cheaper competitors |
Regional medical tourism, Malaysia | Sunway Medical Centre; Gleneagles/Pantai (IHH); Beacon Hospital | Hospital groups | Same competitive dynamic |
Hong Kong oncology | Hong Kong Integrated Oncology Centre (now New Frontier) | Private | Former associate |
CGT CDMO | Global and regional viral vector CDMOs | Contract manufacturers | CellVec is sub-scale. Named competitors are not disclosed by the company. |
Peer Comparison FY2024
| Metric | TalkMed FY2024 (Dec) | Raffles Medical FY2024 (Dec) | IHH Healthcare FY2024 (Dec) | Thomson Medical FY2024 (Jun) |
|---|---|---|---|---|
Revenue | S$78.2M | S$751.6M | RM24.38B | S$351.2M |
Revenue growth | -6.7% | +6.3% | +16% | -1.3% |
EBITDA | S$38.6M (derived) | S$125.7M | about RM5.44B | S$102.4M |
EBITDA margin | 49.4% (derived) | 16.7% (derived) | about 22% (derived) | 29.2% (derived) |
Net margin | 56.0% reported; about 36.9% adjusted | 8.3% (PATMI) | about 10.9% headline (derived) | 5.6% (PAT, derived) |
Balance sheet | Net cash S$74.1M; no borrowings | Not analysed | Not analysed | Net debt to EBITDA rose to 9.2x (Jun 2024, per FSMOne) |
Recent Developments
As a private company since September 2025, TalkMed issues no regulatory filings.
Not publicly disclosed post-delisting: * financial results, layoffs or hiring, guidance, contract changes with Parkway, litigation, and leadership changes at the TalkMed entity level.



